TG4001 box

TG4001

A therapeutic vaccine in Phase II

TG4001 targets HPV-induced anogenital cancers.

  More information

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2025 Transgene - All rights reserved
Credits